IAM217
Asset
Inhibits KIF18A to selectively disrupt mitotic spindle function in cancer cells
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- KIF18A
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Ovarian cancer
Phase 1, businesswire.com, 5 Oct 2026
Triple-negative breast cancer
Phase 1, businesswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors5
Every asset’s record: target, stage, trials and the evidence behind it.